Paul Tudor Jones's ABT Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 170,337 shares of Abbott Laboratories (ABT) worth $21.34 M, representing 0.04% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 39 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in ABT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 428,413 shares. Largest reduction occurred in Q2 2024, reducing 295,721 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +170,337 | New Buy | 170,337 | $125.29 |
| Q4 2024 | -112,232 | Sold Out | 0 | $0.00 |
| Q3 2024 | -85,097 | Reduce 43.12% | 112,232 | $114.01 |
| Q2 2024 | -295,721 | Reduce 59.98% | 197,329 | $103.91 |
| Q1 2024 | +428,413 | Add 662.80% | 493,050 | $113.66 |
| Q4 2023 | -88,590 | Reduce 57.82% | 64,637 | $110.07 |
| Q3 2023 | +153,227 | New Buy | 153,227 | $96.85 |
| Q2 2023 | -139,628 | Sold Out | 0 | $0.00 |
| Q1 2023 | +139,628 | New Buy | 139,628 | $0.10 |
| Q4 2022 | -33,021 | Sold Out | 0 | $0.00 |
| Q3 2022 | +33,021 | New Buy | 33,021 | $96.76 |
| Q2 2022 | -93,944 | Sold Out | 0 | $0.00 |
| Q1 2022 | +93,944 | New Buy | 93,944 | $118.36 |
| Q4 2021 | -68,072 | Sold Out | 0 | $0.00 |
| Q3 2021 | +36,722 | Add 117.14% | 68,072 | $118.12 |
| Q2 2021 | +17,196 | Add 121.49% | 31,350 | $115.92 |
| Q1 2021 | -52,577 | Reduce 78.79% | 14,154 | $119.82 |
| Q4 2020 | +66,731 | New Buy | 66,731 | $109.48 |
| Q3 2020 | -30,325 | Sold Out | 0 | $0.00 |
| Q2 2020 | +30,325 | New Buy | 30,325 | $91.44 |
| Q1 2020 | -59,324 | Sold Out | 0 | $0.00 |
| Q4 2019 | +59,324 | New Buy | 59,324 | $86.86 |
| Q3 2018 | -5,400 | Sold Out | 0 | $0.00 |
| Q2 2018 | +5,400 | New Buy | 5,400 | $60.93 |
| Q2 2017 | -8,900 | Sold Out | 0 | $0.00 |
| Q1 2017 | -7,900 | Reduce 47.02% | 8,900 | $44.38 |
| Q4 2016 | +200 | Add 1.20% | 16,800 | $38.39 |
| Q3 2016 | -9,700 | Reduce 36.88% | 16,600 | $42.29 |
| Q2 2016 | +26,300 | New Buy | 26,300 | $39.32 |
| Q1 2016 | -13,100 | Sold Out | 0 | $0.00 |
| Q4 2015 | -46,614 | Reduce 78.06% | 13,100 | $44.89 |
| Q3 2015 | +46,014 | Add 335.87% | 59,714 | $40.23 |
| Q2 2015 | +4,400 | Add 47.31% | 13,700 | $49.05 |
| Q1 2015 | +1,091 | Add 13.29% | 9,300 | $46.34 |
| Q4 2014 | +39 | Add 0.48% | 8,209 | $45.07 |
| Q3 2014 | -17,260 | Reduce 67.87% | 8,170 | $41.62 |
| Q2 2014 | +25,430 | New Buy | 25,430 | $40.90 |
| Q1 2014 | -6,100 | Sold Out | 0 | $0.00 |
| Q4 2013 | +6,100 | New Buy | 6,100 | $38.36 |
Paul Tudor Jones's Abbott Laboratories Investment FAQs
Paul Tudor Jones first purchased Abbott Laboratories (ABT) in Q4 2013, acquiring 6,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Abbott Laboratories (ABT) for 39 quarters since Q4 2013.
Paul Tudor Jones's largest addition to Abbott Laboratories (ABT) was in Q1 2024, adding 493,050 shares worth $56.04 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 170,337 shares of Abbott Laboratories (ABT), valued at approximately $21.34 M.
As of the Q4 2025 filing, Abbott Laboratories (ABT) represents approximately 0.04% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Abbott Laboratories (ABT) was 493,050 shares, as reported at the end of Q1 2024.